Close Menu

NEW YORK (GenomeWeb) – SEngine Precision Medicine said today that its Seattle-based laboratory has received CLIA certification.

The company's primary test offering, called PARIS, combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.

SEngine said that its CLIA Laboratory now simultaneously screens up to 120 individual drugs and selected drug combinations.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.